ABSTRACT
To eradicate most infectious diseases, mathematical modelling of contagious diseases has revealed that a combination of quarantine, vaccination, and cure is frequently required. However, eradicating the disease will remain a difficult task if they aren't provided at the appropriate time and in the right quantity. Control analysis has been shown to be an effective way for discovering the best approaches to preventing the spread of contagious diseases through the development of disease preventive interventions. The method comprises reducing the cost of infection, implementing control measures, or both. In order to gain a better understanding of COVID-19's future dynamics, this study presents a compartmental mathematical model. The problem is modelled as a highly nonlinear coupled system of classical order ODEs, which is then generalised using the Mittag-Leffler kernel's fractal-fractional derivative. The uniqueness of the fractional model under discussion has also been demonstrated. The boundedness and non-negativity of the considered model are also established. The next generation technique is used to examine basic reproduction, anddisease free and endemic equilibrium. We used reported cases from Australia in this investigation due to the high risk of infection. The reported cases are considered between 1st July 2021 and 20th August 2021. On the basis of previous data, the spread of infection is predicted for the next 600 days which is shown through different graphs. The graphical solution of the considered nonlinear model is obtained via numerical scheme by implementing the MATLAB software. Based on the fitted values of parameters, the basic reproduction number R0 is calculated as R0≈1.58276. Furthermore, the impact of fractional and fractal parameter on the disease spread among different classes is demonstrated. In addition, the impact of quarantine and vaccination on infected people is dramatically depicted. It's been argued that public awareness of the quarantine and effective vaccination can drastically reduce infection rates in the population.
ABSTRACT
AIM: The purpose of this review is to discuss the current status of local and international efforts undergoing clinical trials aiming at developing a Coronavirus Disease-2019 (COVID-19) vaccine, and to highlight the anticipated challenges of this vaccine globally and in Saudi Arabia. PRESENT FINDINGS: COVID-19 vaccine development efforts started in early January 2020 when Chinese scientists shared the Coronavirus genomic sequence in public domain. Approximately 321 research groups initiated the search for a vaccine, out of which 41 have reached phase I/II trails and 11 reached phase-III clinical trials, including approved vaccines for early to limited use. Out of these projects are two labs in the Kingdom of Saudi Arabia still in early stages of development of a COVID-19 vaccine. Several vaccine attempts are being tested from traditional, attenuated virus methods, to new nucleic acid-based designs. However, no vaccine has yet completed clinical trials and reached public domain.In spite of the challenges faced during previous vaccine trials, researchers have found that Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 is structurally similar to the (SARS-CoV-1) and the Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), which caused epidemics in 2003 and 2012 respectively. Both SARS strains show identical affinity towards the type-II alveolar pneumocytes angiotensin converting enzyme-2 (ACE-2) receptor binding domains and therefore, similar pathogenicity. The race to develop the vaccine is predominantly for individuals at high risk of developing the infection, i.e. population groups who are most susceptible to experiencing fatal symptoms of the coronavirus. These include patients with comorbidities, above the age of 60 years and people at risk of contracting large viral loads, such as healthcare providers caring for critical admissions in in-patient wards, Intensive Care Units and Emergency Room settings. SUMMARY: Many different vaccine strategies are under development throughout different stages of the research timeline; however, it is estimated that none will show favorable results before end of 2020. For any immunization or interventional prevention/therapy system to reach the public and patients at high risk, it needs to undergo multiple phase trials to ensure safety and effectiveness. In this scoping review we aim to map the literature on COVID-19 vaccines and provide recommendations related to gaps in research, applicability and expected challenges for implementation of nationwide vaccination in Saudi Arabia.
ABSTRACT
The first case of COVID-19 was announced at the end of year 2019, and later many cases were identified worldwide. In Saudi Arabia, the first case was announced on 2 March 2020. To prevent the spread of this pandemic disease, many precautionary actions were taken by Saudi government. One of these actions was closing public and private schools and universities and transfer the educational activities to virtual platforms. All colleges of Pharmacy in Saudi Arabia, whether the 21 public or the eight private ones, were affected by those sudden transitions and their responses varied according to their preparedness levels. Here we shared our experience in king Saud University in the curricular components of pharmacy school that includes classroom teaching, laboratory teaching, experiential training, assessment, and extracurricular activity and student support during COVID-19 compulsory lockdown. Lastly, we presented the lesson learned toward pharmacy education from COVID-19 pandemic.